Summary: A liver-speciˆc transporter organic anion transporting polypeptide 1B1 (OATP1B1, also known as OATP-C) is encoded by SLCO1B1 and mediates uptake of various endogenous and exogenous compounds from blood into hepatocytes. In this study, 15 SLCO1B1 exons (including non-coding exon 1) and their ‰anking introns were comprehensively screened for genetic variations in 177 Japanese subjects. Sixty-two genetic variations, including 28 novel ones, were found: 7 in the 5′ -‰anking region, 1 in the 5′ -untranslated region (UTR), 13 in the coding exons (9 nonsynonymous and 4 synonymous variations), 5 in the 3′ -UTR, and 36 in the introns. Five novel nonsynonymous variations, 311T＞A (Met104Lys), 509T＞C (Met170Thr), 601A＞G (Lys201Glu), 1553C＞T (Ser518Leu), and 1738C＞T (Arg580Stop), were found as heterozygotes. The allele frequencies were 0.008 for 1738C＞T (Arg580Stop) and 0.003 for the four other variations. Arg580Stop having a stop codon at codon 580 results in loss of half of transmembrane domain (TMD) 11, TMD12, and a cytoplasmic tail, which might aŠect transport activity. In addition, novel variations, IVS12-1G＞T at the splice acceptor site and -3A＞C in the Kozak motif, were detected at 0.003 and 0.014 frequencies, respectively. Haplotype analysis using -11187G＞A, -3A＞C, IVS12-1G＞T and 9 nonsynonymous variations revealed that the haplotype frequencies for * 1b, * 5, * 15, and * 17 were 0.469, 0.000 (not detected), 0.037, and 0.133, respectively. These data would provide fundamental and useful information for pharmacogenetic studies on OATP1B1-transported drugs in Japanese.
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Introduction
Organic anion transporting polypeptide 1B1 (OATP1B1, also known as OATP-C, OATP2 and LST-1) is a liver-speciˆc transporter expressed on the sinusoidal membrane and mediates uptake of various endogenous and exogenous compounds from blood into hepatocytes. 1, 2) Exogenous compounds include several 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (such as pravastatin), an active metabolite of irinotecan SN-38, methotrexate, and rifampicin; endogenous substrates include bilirubin and bilirubin glucuronide, cholate, leukotriene C4, and estradiol17b-glucuronide. 1, 2) OATP1B1 protein (691 amino acid residues) is encoded by SLCO1B1, which consists of 15 exons (including non-coding exon 1) and spans approximately 109 kb on chromosome 12p12.2-p12.1. Similar to other OATP family members, this transporter is predicted to have 12 transmembrane domains (TMDs). 1, 3) Several genetic polymorphisms and haplotypes with functional signiˆcance are already known in SLCO1B1. In Japanese, two haplotypes with nonsynonymous variations *1b and *15 have been frequently reported. The SLCO1B1 * 1b haplotype with 388AÀG (Asn130Asp) has been shown to have no altered transport activity from in vitro expression systems.
2,4-7)
Recently, however, an in vivo study has suggested that the area under the concentration-time curve (AUC) of pravastatin is signiˆcantly lower in *1b/*1b subjects than in *1a/*1a subjects, suggesting increased transport activity possibly through increased protein expression. 8) Another major haplotype, SLCO1B1 * 15 harboring both 388AÀG (Asn130Asp) and 521TÀC (Val174Ala), has been reported to show impaired plasma membrane expression 6) and reduced transport activity in vitro, 6, 7) probably due to the Val174Ala substitution. 2, 4, 6) The association of the * 15 haplotype with signiˆcant increases in AUC was reported for pravastatin, 2, 9) and irinotecan and SN-38.
10) The haplotype frequencies of *1b, *5 (with 521TÀC, Val174Ala), and *15 were reported to be 0.46-0.54, 0.00-0.01, and 0.10-0.15, respectively, in Japanese. 5, 11) Recently, the SLCO1B1*17 haplotype having 388AÀG (Asn130Asp), 521TÀC (Val174Ala), and -11187GÀA was also shown to increase the AUC of pravastatin 9) and likely reduces the pravastatin e‹cacy on cholesterol synthesis, 12) although the eŠect of -11187GÀA on transcriptional activity has not been clariˆed in vitro. The frequency of *17 has not, however, been reported in Japanese.
In this study, all 15 exons and their surrounding introns were resequenced for comprehensive screening of genetic variations in SLCO1B1. Sequence analysis detected 62 variations including 5 novel nonsynonymous ones from 177 Japanese subjects. Haplotype frequencies of *1b, *5, *15, and *17 were also estimated.
Materials and Methods
Human genomic DNA samples: One hundred seventy-seven Japanese cancer patients administered irinotecan participated in this study and provided written informed consent. The ethical review boards of the National Cancer Center and the National Institute of Health Sciences approved this study. Whole blood was collected from the patients prior to the administration of irinotecan, and genomic DNA was extracted from blood leukocytes by standard methods.
PCR conditions for DNA sequencing and haplotype analysis: First, two sets of multiplex PCR were performed to amplify all 15 exons of SLCO1B1 from 100 ng of genomic DNA using 1.25 units of Z-Taq (Takara Bio. Inc., Shiga, Japan) with 0.2 mM each of the mixed primers (Mix 1 and Mix 2) designed in the intronic regions as listed in Table 1 (1st PCR). Mix 1 contained primers for amplifying exons 1 and 2, and 12 to 14, and Mix 2 contained primers for exons 3 to 7, 8 to 11, and 15. Theˆrst PCR conditions consisted of 30 cycles of 98 9 C for 5 sec, 559 C for 10 sec, and 729 C for 190 sec. Next, each exon was ampliˆed separately by Ex-Taq (0.625 units, Takara Bio. Inc.) with appropriate primers (0.5 mM) designed in the introns ( Table 1 , 2nd PCR). The conditions for the second round PCR were 949 C for 5 min, followed by 30 cycles of 949 C for 30 sec, 559 C for 1 min, and 729 C for 2 min, and then aˆnal extension at 729 C for 7 min. For ampliˆcation of exons 10 and 13, PCR was carried out under the following conditions: 949 C for 5 min followed by 33 cycles of 949 C for 30 sec, 559 C for 1 min, and 729 C for 30 sec, and then â nal extension at 729 C for 7 min. Following PCR, the products were treated with a PCR Product Pre-Sequencing Kit (USB Co., Cleveland, OH, USA) and directly sequenced on both strands using an ABI BigDye Terminator Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) with the sequencing primers listed in Table 1 (Sequencing). Excess dye was removed by a DyeEx96 kit (Qiagen, Hilden, Germany), and the eluates were analyzed on an ABI Prism 3700 DNA Analyzer (Applied Biosystems). All variations were conˆrmed by sequence analysis of PCR products generated by new ampliˆcation of the original genomic DNA templates. Furthermore, rare SNPs found in single patients as heterozygotes were conˆrmed by sequencing the PCR fragments produced by the ampliˆcation with a highˆdelity DNA polymerase KOD-Plus-(TOYOBO, Tokyo, Japan).
Hardy-Weinberg equilibrium was analyzed by SNPAlyze version 3.1 (Dynacom Co., Yokohama, Japan). Estimation of SLCO1B1 haplotypes was performed by an expectation-maximization based program, LDSUP-PORT software.
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Results and Discussion
Sequence analysis from 177 Japanese subjects resulted in the identiˆcation of 62 genetic variations, including 28 novel ones ( Table 2) . Of these variations, 7 were located in the 5?-‰anking region, 1 in the 5?-untranslated region (UTR), 13 in the coding exons (9 nonsynonymous and 4 synonymous variations), 5 in the 3?-UTR, and 36 in the introns. All detected variations were in Hardy-Weinberg equilibrium (pÀ0.05).
Of the 9 nonsynonymous variations, 5 variations were novel: 311TÀA (Met104Lys), 509TÀC (Met170Thr), 601AÀG (Lys201Glu), 1553CÀT (Ser518Leu), and 1738CÀT (Arg580Stop). All of these variations were found as heterozygotes with frequencies of 0.008 for 1738CÀT (Arg580Stop) and 0.003 for the four other variations. Arg580, residing in TMD11, is conserved among human, rat and mouse OATP families.
1) The change from arginine residue to the immature termination codon leads to loss of this conserved amino acid along with the subsequent half of TMD11, TMD12 and the cytoplasmic tail, 1) which very likely aŠects transport activity. Other variations 311TÀA (Met104Lys), 509TÀC (Met170Thr), 601AÀG (Lys201Glu), and 1553CÀT (Ser518Leu) are located in TMD3, TMD4, the short cytoplasmic loop between TMD4 and TMD5, and the large extracellular loop between TMD9 and TMD10, respectively. 1) Using the PolyPhen program (http://genetics.bwh.harvard.edu/pph/) to predict the functional eŠects of the four amino acid substitutions, three substitutions, Met104Lys, Met170Thr and Ser518Leu, were expected to alter the protein function based on the PSIC (position-speciˆc independent count) score diŠerences derived from multiple alignments. The functional signiˆcance of these 5 novel nonsynonymous variations should be clariˆed in the future. In addition, a novel variation at the splice acceptor site, IVS12-1 GÀT, was detected at a 0.003 frequency. This variation might cause aberrant splicing of SLCO1B1 pre-mRNA and thus in‰uence the expression level of active protein.
Furthermore, -3AÀC might reduce translational e‹ciency since this purine-to-pyrimidine alteration results in a deviation from the Kozak motif, where the purine nucleotide at position -3 from the translational initiation codon is important. 14) Four known variations, 388AÀG (Asn130Asp), 452AÀG (Asn151Ser), 521TÀC (Val174Ala), and 1007CÀG (Pro336Arg), were detected at 0.667, 0.034, 0.175, and 0.006 frequencies, respectively, which are similar to the Japanese data reported previously. 5, 11) The allele frequencies of 521TÀC (Val174Ala) in Japanese (0.11-0.18) are comparable to those in other Asian populations (0.04-0.25) and Caucasians (0.14-0.22), but higher than that in African-Americans (0.02). 10, 15, 16) The frequencies of 388AÀG (Asn130Asp) in Japanese (0.63-0.67) are also similar to those in other Asians (0.57-0.88) and African-Americans (0.75), but higher than those in Caucasians (0.30-0.51). 10, 15, 16) Variations 452AÀG (Asn151Ser) and 1007CÀG (Pro336Arg) have not been reported in other ethnic populations. Analysis of these four known variations with PolyPhen program showed that only Val174Ala was expected to alter protein function, which is consistent with the previous functional analysis. 2, 4, 6) Variations 1454GÀT (Cys485Phe) and 1628TÀG (Leu543Trp) previously reported in Japanese were not detected in this study. 11, 17) Hepatocyte nuclear factor 1a is known to transactivate SLCO1B1 through binding to the promoter region (from -10432 to -10420 from the translational start codon); 18) however, no variation was found in this region.
Using -11187GÀA, -3AÀC, IVS12-1GÀT and 9 nonsynonymous variations, diplotype conˆguration was estimated for each subject. The conˆguration was estimated with À0.99 probabilities for all but four subjects. The predicted haplotype frequencies for *1b [harboring 388AÀG (Asn130Asp)], *5 [harboring 521TÀC (Val174Ala)], * 15 [harboring 388AÀG (Asn130Asp) and 521TÀC (Val174Ala)] and *17 [harboring -11187GÀA, 388AÀG (Asn130Asp), and 521TÀC (Val174Ala)] were 0.469, 0.000 (not detected), 0.037 and 0.133, respectively. The haplotype frequencies for * 1b and * 5 are similar to those in the previous studies in Japanese. 5, 11) The *17 frequency is higher than those in Chinese (0.085), Finnish Caucasians (0.069), Malay (0.029) and Indians (0.009). 15, 16) It should be noted that 76z (n＝47 alleles) of 521TÀC (Val174Ala)-bearing haplotypes were assigned as * 17, and 21z (n＝13) of them as *15. The remaining two (3z) was estimated to exist with 1007CÀG (Pro336Arg) and * 17 variations [-11187GÀA, 388AÀG (Asn130Asp), and 521TÀC (Val174Ala)] on the same chromosomes. The *17 ratio in 521TÀC (Val174Ala)-bearing haplotypes is similar to that in Chinese (65z), but higher than those in Finnish Caucasians (34z), Malay (26z) and Indians (14z). 15, 16) Variation 452AÀG (Asn151Ser, n＝12 alleles) or 1738CÀT (Arg580Stop, n＝3) were predicted to be on the * 1a background (no other variation).
In conclusion, 62 genetic variations were identiˆed, including 28 novel ones, in SLCO1B1. One novel nonsynonymous variation results in a truncated protein and four novel nonsynonymous variations result in amino acids substitutions. In addition, novel variations IVS12-1 GÀT at the splice acceptor site and -3AÀC in the Kozak motif were detected. Approximately 76z of 521TÀC (Val174Ala)-bearing haplotypes were assigned as *17 and the majority of the remaining haplotypes were * 15. This information would be useful for pharmacogenetic studies to investigate the associations of SLCO1B1 variations with interindividual diŠerences in drug disposition.
